Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.
consensus
definitions
diagnosis
invasive fungal diseases
research
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
12 09 2020
12 09 2020
Historique:
received:
27
05
2019
accepted:
08
10
2019
pubmed:
6
12
2019
medline:
28
4
2021
entrez:
6
12
2019
Statut:
ppublish
Résumé
Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Sections du résumé
BACKGROUND
Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.
METHODS
To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.
RESULTS
There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.
CONCLUSIONS
These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Identifiants
pubmed: 31802125
pii: 5645434
doi: 10.1093/cid/ciz1008
pmc: PMC7486838
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1367-1376Subventions
Organisme : Medical Research Council
ID : MR/N006364/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N006364/2
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Clin Microbiol. 2010 Apr;48(4):1231-40
pubmed: 20147637
AJR Am J Roentgenol. 2014 Jul;203(1):180-9
pubmed: 24951213
BMC Infect Dis. 2009 Nov 23;9:183
pubmed: 19930662
Transpl Infect Dis. 2012 Oct;14(5):510-8
pubmed: 22548840
J Clin Microbiol. 2012 Apr;50(4):1258-63
pubmed: 22301025
Cochrane Database Syst Rev. 2015 Dec 30;(12):CD007394
pubmed: 26716951
PLoS One. 2013;8(3):e59237
pubmed: 23533607
Clin Infect Dis. 2005 Jun 15;40(12):1762-9
pubmed: 15909264
Clin Infect Dis. 2015 Mar 15;60(6):892-9
pubmed: 25586686
Clin Radiol. 2012 Dec;67(12):1179-86
pubmed: 22766482
Chest. 2010 Oct;138(4):817-24
pubmed: 20453070
J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e123-e133
pubmed: 28903523
Transpl Infect Dis. 2010 Aug 1;12(4):309-15
pubmed: 20202177
Clin Infect Dis. 1995 Jul;21(1):28-34; discussion 35-6
pubmed: 7578756
Emerg Infect Dis. 2011 Oct;17(10):1855-64
pubmed: 22000355
J Clin Microbiol. 2018 Apr 25;56(5):
pubmed: 29444828
J Antimicrob Chemother. 2017 Nov 1;72(11):3047-3050
pubmed: 28961889
Am J Clin Pathol. 2013 Aug;140(2):203-8
pubmed: 23897255
Lancet Infect Dis. 2004 Jun;4(6):349-57
pubmed: 15172343
Clin Infect Dis. 2009 Apr 1;48(7):856-62
pubmed: 19222372
J Clin Microbiol. 2016 Feb;54(2):428-31
pubmed: 26659218
J Pediatric Infect Dis Soc. 2017 Sep 1;6(suppl_1):S22-S31
pubmed: 28927203
PLoS One. 2011;6(12):e28467
pubmed: 22164295
Pediatrics. 2003 Sep;112(3 Pt 1):634-40
pubmed: 12949295
Transpl Infect Dis. 2014 Apr;16(2):213-24
pubmed: 24589027
Clin Infect Dis. 2014 Jan;58(1):74-7
pubmed: 24114736
Clin Infect Dis. 2004 Nov 15;39(10):1467-74
pubmed: 15546083
Am J Clin Pathol. 2019 Feb 4;151(3):275-285
pubmed: 30307463
Br J Haematol. 2002 May;117(2):379-86
pubmed: 11972521
Crit Rev Microbiol. 2015 Feb;41(1):124-34
pubmed: 23799871
Crit Rev Microbiol. 2009;35(4):283-309
pubmed: 19821642
PLoS One. 2012;7(8):e43347
pubmed: 22905261
Clin Infect Dis. 2016 Nov 15;63(10):1340-1348
pubmed: 27567122
J Pediatric Infect Dis Soc. 2017 Sep 1;6(suppl_1):S32-S44
pubmed: 28927202
Lancet Infect Dis. 2009 Feb;9(2):89-96
pubmed: 19179225
Pediatr Infect Dis J. 2012 Dec;31(12):1252-7
pubmed: 22982980
Chest. 2012 May;141(5):1260-1266
pubmed: 22016487
Clin Infect Dis. 2000 Aug;31(2):499-508
pubmed: 10987712
Clin Infect Dis. 2006 Oct 15;43(8):1077-80
pubmed: 16983624
J Infect Dis. 2012 Oct 1;206(7):1128-37
pubmed: 22829648
Clin Infect Dis. 2010 Apr 15;50(8):1101-11
pubmed: 20218876
Clin Infect Dis. 2019 Jan 7;68(2):188-195
pubmed: 29878145
Clin Infect Dis. 1993 Nov;17 Suppl 2:S416-22
pubmed: 8274607
J Antimicrob Chemother. 2018 Mar 1;73(suppl_4):iv2-iv5
pubmed: 29608754
Med Mycol. 2010 Dec;48(8):1112-5
pubmed: 20438294
Am J Clin Pathol. 2016 Jun;145(6):858-61
pubmed: 27247378
Clin Infect Dis. 2012 Mar 1;54(5):633-43
pubmed: 22198786
Clin Infect Dis. 2015 Mar 1;60(5):713-20
pubmed: 25414266
Mycoses. 2017 May;60(5):310-319
pubmed: 28240390
J Clin Microbiol. 2015 Mar;53(3):868-74
pubmed: 25568431
J Clin Microbiol. 2017 Aug;55(8):2356-2366
pubmed: 28515217
Mycoses. 2019 Apr;62(4):310-319
pubmed: 30426598
Pediatr Radiol. 2003 Jul;33(7):453-60
pubmed: 12739082
Eur J Radiol. 1992 Jan-Feb;14(1):37-40
pubmed: 1563402
Emerg Infect Dis. 2018 Apr;24(4):758-761
pubmed: 29553321
Clin Infect Dis. 2018 May 17;66(11):1678-1686
pubmed: 29438475
PLoS One. 2012;7(8):e42282
pubmed: 22879929
Clin Infect Dis. 2015 Oct 15;61(8):1293-303
pubmed: 26113653
Eur Radiol. 2018 Feb;28(2):788-795
pubmed: 28812135
J Pediatric Infect Dis Soc. 2012 Jun;1(2):103-11
pubmed: 23687575
Med Mycol Case Rep. 2019 Jan 14;24:5-8
pubmed: 30733915
Clin Microbiol Infect. 2015 Jul;21(7):684.e11-8
pubmed: 25882362
Med Mal Infect. 2014 May;44(5):185-98
pubmed: 24630595
J Pediatric Infect Dis Soc. 2017 Sep 1;6(suppl_1):S3-S11
pubmed: 28927200
Clin Infect Dis. 2010 Apr 15;50(8):1091-100
pubmed: 20218877
J Clin Microbiol. 2016 Nov;54(11):2707-2710
pubmed: 27558179
PLoS Negl Trop Dis. 2018 Mar 8;12(3):e0006173
pubmed: 29518092
Clin Infect Dis. 2014 Dec 15;59(12):1696-702
pubmed: 25165088
J Clin Microbiol. 2014 Oct;52(10):3731-42
pubmed: 25122854
J Pediatric Infect Dis Soc. 2016 Sep;5(3):277-86
pubmed: 26407252
Transpl Infect Dis. 2017 Apr;19(2):
pubmed: 28035717
PLoS One. 2013 Sep 04;8(9):e73099
pubmed: 24023814
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
J Clin Microbiol. 2012 Jan;50(1):7-15
pubmed: 22075593
J Clin Microbiol. 2014 May;52(5):1737-40
pubmed: 24574295
Pediatrics. 2008 May;121(5):e1286-94
pubmed: 18450871
Med Mycol. 2015 May;53(4):313-37
pubmed: 25802363
Clin Microbiol Infect. 2013 Jan;19(1):39-49
pubmed: 22329494